Dupilumab for a Novel Treatment for Necrobiosis Lipoidica: Case Report

Background This paper describes a case of necrobiosis lipoidica (NL) which was successfully treated with dupilumab. NL can be a difficult and chronic disease, often with limited treatment options. Dupilumab is a biologic typically used for atopic dermatitis, but given its novel pathway, it has been used in a number of other conditions. Case Presentation We describe a patient with inflammation on her legs, which was biopsied and consistent with NL. Treatments, including topical steroids, were started, but there was no improvement, therefore, dupilumab was discussed. She agreed with the treatment and dupilumab injections, and she reported a decrease in redness and improvement in her NL. Conclusion With this report, hopefully, there will be another option for the treatment of NL and different and novel uses for dupilumab.

Authors

Institutions

Publication Details

Journal
The Open Dermatology Journal
Published
2024-12-31
DOI
https://doi.org/10.2174/0118743722350879241209044938
Primary Topic
Skin Diseases and Diabetes
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Dupilumab for a Novel Treatment for Necrobiosis Lipoidica: Case Report

Ryan Sato, Junko Sato, Hailey Monaco
The Open Dermatology Journal
Skin Diseases and Diabetes
article

Dupilumab for a Novel Treatment for Necrobiosis Lipoidica: Case Report

Ryan Sato, Junko Sato, Hailey Monaco
article en

Abstract

Background This paper describes a case of necrobiosis lipoidica (NL) which was successfully treated with dupilumab. NL can be a difficult and chronic disease, often with limited treatment options. Dupilumab is a biologic typically used for atopic dermatitis, but given its novel pathway, it has been used in a number of other conditions. Case Presentation We describe a patient with inflammation on her legs, which was biopsied and consistent with NL. Treatments, including topical steroids, were started, but there was no improvement, therefore, dupilumab was discussed. She agreed with the treatment and dupilumab injections, and she reported a decrease in redness and improvement in her NL. Conclusion With this report, hopefully, there will be another option for the treatment of NL and different and novel uses for dupilumab.

The Open Dermatology JournalVol. 18(1)
University of Hawaiʻi at Mānoa (US), Northeastern University (US), New York Medical College (US)
Good health and well-being
Openalex Percentile: Top 49%
Skin Diseases and Diabetes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.